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ABSTRACT
Background. Tuberculosis (TB) is an important infection encountered posttransplantation,
especially among patients in developing countries, where there are high incidences of
morbidity and mortality.
Materials and Methods. One hundred and twenty subjects (1%) from 15 major kidney
transplantation centers in Iran from 1984 to 2003 were compared with 440 controls who
were matched for operative time, treatment center, and surgical team.
Results. Mean ages of research subjects and controls were 38.6 and 36.6 years (P  .04),
respectively. The mean duration of pretransplantation hemodialysis was 29 months (range,
2 to 192 months) in research subjects and 20 months (range, 1 to 180 months) in controls
(P  .003). Positive past history of tuberculosis was detected in 4 (3.3%) research subjects
and in 7 (1.5%) controls (P  .2). Fifty-two research subjects (43.3%) and 241 controls
(54.8%) had pretransplantation purified protein derivative of tuberculin less than 5 mm
(P  .02). Mean dosages of initial and maintenance immunosuppressive drugs in research
subjects and in controls were not significantly different. Sixty research subjects (50%) and
152 controls (34.5%) had rejection prior to diagnosis of TB (P  .03).
Conclusion. To our knowledge, this is the first study that demonstrates an increased risk
of posttransplant TB by prolonged duration of pretransplant hemodialysis and number of
posttransplant rejection episodes. Further study is needed to clarify these findings
specifically with respect to various immunosuppressive regimens.
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3042 BASIRI, HOSSEINI MOGHADDAM, SIMFOROOSH ET ALUBERCULOSIS (TB) is an uncommon infectious
complication after kidney transplantation and may
eopardize the function of the renal allograft. Both primary
nfection and reactivation of Mycobacterium tuberculosis
mt) infection in kidney transplant patients are common
herapeutic problems, especially in those receiving multiple
mmunosuppressive drugs in developing countries.
Reactivation of dormant infection is the usual mode of
cquisition, and nosocomial transmission occurs infre-
uently. Donor-transmitted extrapulmonary infection has
een reported.1 Additionally, tuberculous nephropathy2
nd granulomatous interstitial nephritis3 involving recipi-
nts have been described.
Immunosuppression assists reactivation of latent tuber-
ulosis or progression of acquired disease in kidney trans-
lant recipients.4,5 Apart from the usual pulmonary presen-
ations, hematogenous spread of tuberculosis frequently
ccurs in these cases,6 affecting joints or bone marrow,7
ervous system,8,9 and the kidney allograft.4 These ex-
rapulmonary manifestations as well may lead to a delay in
he diagnosis and, therefore, enhanced morbidity and mor-
ality of kidney recipients.
Most previous studies on posttransplant TB are case
eports and case series. Probable risk factors for TB have
ot been compared with a control population of renal
ransplant recipients. The present study was undertaken to
etermine the clinical manifestations and laboratory find-
ngs of TB in renal transplant patients, as well as the
otential risk factors for this disease following transplanta-
ion. To our knowledge, this is the first countrywide,
ase-control study on TB following renal transplantation.
ATERIALS AND METHODS
his case-control study was carried out at 15 university teaching
ospitals. The hospital records and reports of outpatient follow-up
isits of 12,820 patients who received a kidney transplant between
984 and 2003 were reviewed. In addition, we interviewed the
ephrologists who were responsible for visiting all 120 patients with
he diagnosis of posttransplant TB. We selected 440 patient
ontrols who were transplanted at the same time by the same
urgical team. In our study, all kidneys were harvested from living
onors.
Clinical charts and hospital records were reviewed for confirm
B according to our diagnostic criteria, demographic information,
egree of immunosuppression, pre- and posttransplantation reac-
ion to purified protein derivative of tuberculin (PPD), previous
istory of tuberculosis, time to development of tuberculosis, clinical
resentation, laboratory data, radiographic and pathological fea-
ures, sites of involvement, methods for diagnosis, treatment
rotocol, and number of rejection episodes prior to tuberculosis.
According to WHO recommendations, case detection and treat-
ent of TB in our country is performed under a strategy of direct
bserved treatment, short course; therefore, “Once patients with
nfectious TB (bacilli visible in a sputum smear) have been
dentified using microscopy services, health and community work-
rs or trained volunteers observe patients swallowing the full
ourse of the correct dosage of anti-TB medicines.”10
The diagnosis of tuberculosis was considered certain in symp-
omatic patients if Mycobacterium tuberculosis was cultured fromny clinical sample, acid-fast bacilli were seen on smear, polymer-
se chain reaction was positive for M tuberculosis, and granuloma
ith caseating changes as well as acid-fast bacilli were found on
istopathology. In our national health system, the Ziehl-Neelsen
tain method is routinely used for staining; and all patients receive
soniazid (INH), rifampin (RMP), pyrazinamide, and ethambutol
or the first 2 months, and INH and RMP for the subsequent 4
onths.
TB was considered probable in patients whose radiographic and
onspecific laboratory data were supportive of a diagnosis of TB
nd whose clinical pictures were highly suggestive of tuberculosis
hat resolved with specific antituberculous treatment.
Cyclosporine (CsA), azathioprine, and steroids were used during
he study period by the majority of centers. After 1990, the majority
f patients received mycophenolate mofetil instead of azathioprine.
oses of CsA were adjusted to obtain trough plasma levels of 200
o 400 ng/mL (as determined by radioimmunoassay) during the first
onth and 100 to 200 ng/mL thereafter. Rejection episodes were
sually treated with boluses of steroids; cases of steroid-resistant
ejection, received antilymphocyte antibodies-antilymphocyte glob-
lin, antithymocyte globulin (ATG), or OKT3. Since 1985, pre-
ransplantation HIV screening has been performed routinely in all
enters. A positive response to tuberculin (PPD) test was defined as
n induration of 5 mm or more in diameter at 48 to 72 hours after
dministration of five tuberculin units.
We compared the demographic characteristics and clinical and
aboratory variables between control group and kidney transplant
ecipients with TB. All statistical associations were analyzed using
ither the Mann-Whitney or a two-tailed t tests for quantitative
ariables and the chi-square or Fisher’s exact test for qualitative
ariables. P values greater than .05 were considered statistically
ignificant. We calculated odds ratios for all risk factors evaluated
n this study.
ESULTS
mong patients who had received a kidney transplant in 15
niversity teaching hospitals from different geographic ar-
as in Iran between 1984 and 2003, 120 (1%) developed
uberculosis. Clinical findings and main comparisons be-
ween cases and controls are given in Tables 1 and 2,
espectively.
All patients in both groups received prednisolone at
imilar mean doses (1.5 vs 1.9 mg/kg, P  .5; odds ratio
OR]  1.2; 95% confidence interval [Cl95%]  0.7 to 2).
wenty-three patients in the study group (19.2%) and 73
ubjects in the control group (16.6%) received MMF (P .3)
ith similar mean doses (19.5 mg/kg vs 19.25 mg/kg, P  .5).
sA was prescribed in 113 cases (94.2%) and 412 controls
93.6%, P  .5) at identical mean doses (both 3.8 mg/kg).
Table 1. Clinical Findings of Research Subjects and Controls
Symptom Subject (%) Control (%) P value
ough* 59 (49.2) 1 (0.2) .00
putum production 55 (45.8) 1 (0.2) .00
ever 94 (78.3) 2 (0.5) .00
ight sweating 40 (33.3) 1 (0.2) .00
eight loss 40 (33.3) 0 .00
emoptysis 13 (10.8) 0 .00*Cough: 3 weeks cough.
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RISK FACTORS OF TUBERCULOSIS 3043inety-three study patients (77.5%) and 341 controls
77.1%, P  .5) received azathioprine at identical mean
oses (1.7 mg/kg). According to our protocol, all patients
ith rejection received pulses of methylprednisolone (and
arely ATG if needed—one case in each group, 0.8% vs
.2%) or ALG one case and seven controls, 0.8% vs 1.6%,
 .4; OR  1.9, CI95%  0.2 to 15.8).
No patient was positive for HIV in this study. Seventy-
even study patients (64.2%) and 1 patient (0.2%) in the
ontrol group had radiological evidence compatible with
uberculosis (P  .0). Table 3 shows the main radiographic
ndings of study patients and controls.
Six study patients (9%) and six controls (3.1%) had a
istory of TB and of receiving anti-TB medicines (P  .06).
ifty-two study subjects (43.3%) and 241 controls (54.8%)
ad pretransplantation PPD values less than 5 mm (P 
02). In addition, if we change the cutoff point of PPD to 10
m, 48 study subjects (40%) and 221 subjects in the control
roup (50.2%) had pretransplantation PPD levels less than
0 mm (P  .05). Mean time to diagnosis of TB was 15.7
onths (range, 1 to 110 months) after transplantation.
Table 2. Clinical Characteristics of Kidney Transplan
Variable Subject (n  120)
ean age, year (range) 38.6 (1–71)
ex (M/F) 62/58
eight 56.1 (26–96)
iving in rural areas 14 (11.5%)
ype of tuberculosis
Pulmonary 82 (68.3%)
Extrapulmonary 29 (24.2%)
Disseminated 9 (7.5%)
istory of prior renal transplantation 6 (5.2%)
ejection prior to diagnosis of TB 60 (50%)
One episode 32 (26.7%)
Two episodes 16 (13.3%)
Three episodes 7 (5.8%)
Four episodes 2 (1.7%)
Five episodes 3 (2.5%)
istory of tuberculosis
In patient 4 (3.3%)
In first relatives 9 (7.5%)
ean time (mo) of being on
hemodialysis prior to
transplantation
29 (2–192)
*Mann-Whitney U test.
Table 3. Radiological Features of Chest X-ray in Cases and
Controls
Controls (%) Subjects (%) Feature
(0.2) 44 (57.2) Apical infiltration and calcification
17 (22) Pleural effusion
7 (9.1) Apical cavitations
9 (11.7) Miliary patterns
77 TotalISCUSSION
nfection caused by M tuberculosis is noticeable among the
eneral population in Iran.11 Moreover, this microorganism
s clearly a potential pathogen in kidney transplant recipi-
nts.12 TB may present as pulmonary, extrapulmonary, or
isseminated disease during the posttransplantation period.
he increasing global incidence of tuberculosis during the
ast decade13 has revealed the demand to clarify screening
ethods, to have a high index of suspicion, and to begin
soniazid chemoprophylaxis in recipients at high risk for
eactivation of latent infection.
The risk factors for tuberculosis in transplant patients are
s yet poorly defined, although the role of intensified
mmunosuppression for a failing graft appears to be impor-
ant. Although our study had some limitations, to our best
nowledge, it is the first comparative case-control study.
Although older people are relatively immunocompro-
ised, the mean age of persons with TB was similar to the
ontrol group in our study, showing that age, per se, may
ot be an independent risk factor. Similarly, although male
ubjects may be more prone to TB in the general popula-
ion, TB was seen with the same frequency in men and
omen in our study. Therefore, the role of other risk factors
nd immunosuppression seems to be more of a determining
actor.
In fact, the degree of immunosuppression in our research
atients was not higher than that recognized for the control
roup, all recipients received the same immunosuppressive
rugs following transplantation. On the other hand, our
ata agreed with the hypothesis proposed by some re-
ipients With Tuberculosis Compared With Controls
Control (n  440) P value OR
36.6 (8–67) .04*
242/198 .5 0.87 CI95%: 0.58–1.3
57.2 (18–92) .5
50 (12%) .8 0.96, CI95%: 0.5–1.8
21 (5.1%) .9 0.95, CI95%: 0.37–2.4
152 (34.5%) .03
111 (25.2%)
26 (5.9%) 1.89, CI95%: 1.23–2.91
7 (1.6%)
7 (1.6%)
1 (0.2%)
7 (1.5%) .2 2.13, CI95%: 0.5–8.28
17 (3.8%) .15 2.02, CI95%: 0.8–4.95
20 (1–180) .003*t Recearchers that administration of antilymphocyte antibodies
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3044 BASIRI, HOSSEINI MOGHADDAM, SIMFOROOSH ET ALnhances the risk of tuberculosis dissemination.7,14 Because
history of graft rejection and the use of antilymphocyte
lobulins was present more frequently among study com-
ared with control subjects, our findings support the role of
hese compounds as potential risk factors for developing
B. Although coadministration of CsA and rifampin may
ecrease CsA levels in kidney transplantation recipients,
his study was not designed to identify the significance of
his drug interaction and its consequences.
In this study, we found that a longer history of hemodi-
lysis was associated with posttransplant TB compared with
ontrols. To our knowledge, this is the first report demon-
trating an effect of long-term hemodialysis prior to trans-
lantation on the development of posttransplantation TB.
ecause the degree of immunosuppression is enhanced
ith increased durations of hemodialysis, this interval may
nhance the probability of posttransplantation TB.
Prevention of TB in kidney transplantation is a compli-
ated issue. Owing to the underlying hemodialysis and
nd-stage renal disease prior to transplantation, patients
re usually immune compromised, thereby making pre-
ransplant screening using a PPD test unhelpful. This may
e why preoperative PPD skin tests and delayed-type
ypersensitivity reactions are not generally accepted. Our
ndings revealed a lower reaction to PPD among our study
ubjects compared with controls. Because decision making
n initiating INH chemoprophylaxis is usually based on a
PD skin test, one may extrapolate that a smaller number
f study compared with control subjects may have received
NH prior to transplantation. Because of a high risk of
epatotoxicity, chemoprophylaxis in renal transplant recip-
ents is controversial. Even in countries with a high inci-
ence of tuberculosis,15,16 the common trend in the pub-
ished reports is toward avoiding the use of INH. Although
NH prophylaxis was indicated in nearly half of our sub-
ects, a low percentage of patients received this drug in our
tudy. There is a controversy regarding the cutoff point for
PD reactions to initiate chemoprophylaxis among special-
sts working in kidney transplantation in our country.
According to our national guidelines, all candidates for
ransplantation with a PPD greater 5 mm receive INH
rophylaxis. INH prophylaxis may be worthy of being
ecommended in transplant recipients with positive PPD
eactions. Considering the frequency of TB in kidney
ecipients—3 times that of recipients with negative PPD
ests7,8—the American Thoracic Society suggests use of
NH in PPD-positive allograft recipients with previous
ulmonary tuberculosis.17 On the other hand, considering
he elevated risk of hepatotoxicity, some researchers rec-
r
dmmend that regular administration of INH may have a
eleterious effect on a patient’s condition.18
It would be worthwhile to know whether a recipient with
negative tuberculin test who received an organ from a
PD-positive donor7 needs chemoprophylaxis. There are
o data addressing prophylaxis in this condition; future
tudies should examine this question.
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